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Abstracts / Biol Blood Marrow Transplant 21 (2015) S147eS170 S157polymorphism, with the exception of an unexpected ﬁnding
of signiﬁcantly higher relapse in association with MICA
mismatches in 10/10 patients (HR 1.7, 95% CI 1.2-2.4, p¼
0.003) but not in 9/10 patients. There was a suggestion that
MICA mismatches were associated with a higher risk of
aGVHD grades II-IV (HR 1.4, 95% CI 1.1-1.9, p¼ 0.013) but not
grades III-IV and with higher risk of cGVHD (HR 1.8, 95% CI:
1.0-3.1, p value 0.04). There were no signiﬁcant interactions
between MICA mismatches and HLA matching (9/10 vs. 10/
10). There was also a suggestion of an association between
donor MICA-129 non-VV genotypes and slower platelet
engraftment with HR 1.4 (95% CI 1.109-1.985, p¼ 0.02).
Conclusions: In this cohort neither MICA-129 poly-
morphism nor MICA mismatches were associated with HSCT
outcomes at a level that reached the predetermined level of
statistical signiﬁcance. This registry analysis in patients with
ALL, AML and MDS was discordant with prior reports of
single center studies of patients with mixed diagnoses.Figure.188
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Background: Double cord blood transplantation (dCBT) is an
important strategy to overcome dose limitation of single CBT
and extend its availability to a broader range of patients (pts).
The dominance of one of the two CB units occurs as early as
12 days after dCBT, and by day 21, over 80% of transplanted
pts have single unit dominance maintaining long-term he-
matopoiesis. However, outcomes of pts who do not achieve
unit dominance, but rather persistence of both CB units after
dCBT is not known.
Methods: We retrospectively analyzed 105 pts with hema-
tological malignancies who engrafted after dCBT between
2003 through 2014 and investigated the presence of donor T
cell chimerism (TCC) of at least 10% from each CB unit at day
100 +/- 30 after transplant (dTCC). Only pts with progression
free survival at day 100 were evaluable.
Results: Of 105 pts, 10 (9.5%) had dTCC. Median age was 43
(range; 1e73). AMLwas themost commondiagnosis in 57.1% of
the pts followed by ALL in 21.9. Disease status was complete
remission (CR) in 67.6% and active disease in 32.4% of the pts.
Conditioningwasmyeloablative in 73.3% and reduced intensity
in 26.7% due to older age and/or frailty. Immunosuppressive
therapy included mycophenolate mofetil with tacrolimus, and
all pts received anti-thymocyte globulin as a part of the con-
ditioning regimen. Per protocol priority over the years, 72.4% of
the pts had ex-vivo expansion of one of the CB units in
mesenchymal stem cell co-culture. Final median dose of CD34+
and total nucleated cells infused were 0.36x106/kg (0.12-5.35)
and 0.51x107/kg (0.3-1.29) respectively.
Patient, disease and graft characteristics were very similar
between dTCC and single donor TCC (sTCC) pts. However,
compared to sTCC, dTCC pts had better 4/6 HLA matching
between 2 CB units (66.3% vs. 90%, p¼0.1) and less manip-
ulation of one of the CB units with expansion (74.7% vs. 50%,
p¼0.1).Median follow-up was 44.7 months (mo). Transplant out-
comes were similar between dTCC and sTCC pts with 3-year
(yr) overall survival and progression free survival of 40% vs.
41.4% and 40% vs. 32.3% respectively. Incidence of progression
was similar between dTCC and sTCC groups (28.9% vs. 27.6%).
Of 10 pts with dTCC, 3 died within 6 mo after dCBT without
repeat TCC and they were not evaluable for long-term assess-
ment. Among others, 1 pt had autologous recovery with pro-
gression after 6 mo of dCBT. Unit dominance with 100% TCC
was observed in 4 pts within 4 to 20 mo after dCBT; 1 of those
pts progressed 5 mo after unit dominance was established and
another pt died of fungal infection at 15 mo. However, 2 AML
pts showed long-term dTCC with units contributing 58%/42%
and 84%/16% at last evaluation, 4 and 3.2 years after dCBT. They
both remain in CR and free of progression.
Conclusion: The unique situation of TCC from both CB units
around day 100 is not associated with worse transplant
outcomes in pts receiving dCBT. These provocative results
need to be conﬁrmed in larger studies.189
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Background: Availability of suitably HLA-matched unrelated
donors (URD) is a major barrier to allogeneic transplantation
especially in minorities & patients with acute leukemia &
lymphoma requiring urgent transplant. The extent that cord
blood (CB) extends transplant access, however, is not estab-
lished. Moreover, the contribution of the domestic U.S. &
international CB inventories to minority patients is an
important factor in public CB Bank funding considerations.
Methods:We prospectively analyzed the availability of 7-8/8
HLA-matched URDs or 4-6/6 HLA-A,-B antigen, -DRB1 allele
matched CB units in patients with hematologic malignancies
